Tharimmune, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THAR research report →
Price Chart
About the company
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1).
- CEO
- Mark Wendland
- IPO
- 2022
- Employees
- 2
- HQ
- Bridgewater, NJ, US
Get TickerSpark's AI analysis on THAR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $139.94M
- P/E
- -1.49
- PEG
- -0.01
- P/S
- 120.64
- P/B
- 1.12
- EV/EBITDA
- -1.63
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -3595.17%
- Net Margin
- -6559.27%
- ROE
- -29.54%
- ROIC
- -8.14%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-20,106,066
- Net Income
- $-35,916,250-194.5%
- EPS
- $-1.12+88.1%
- OCF Growth
- -47.9%
- FCF Growth
- -47.9%
- 52W High
- $9.08
- 52W Low
- $0.95
- 50D MA
- $3.47
- 200D MA
- $2.73
- Beta
- 1.45
- RSI (14)
- 63
- Avg Volume
- 850.30K
No earnings-call transcripts are available for THAR yet.
- Free Float
- 73.1%
- Shares Outstanding
- 39.53M
- Float Shares
- 28.90M
Held by 15 ETFs
Biggest fund positions in THAR by dollar value.
Our THAR coverage
Recent articles, reports, and earnings notes.
No research on THAR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate THAR report →Tharimmune Highlights Canton Network Q1 Growth, Tokenomics Shift and Validator Locking in Webinar
defenseworld.net · Apr 27
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
prnewswire.com · Feb 17
Catherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio Impact
gurufocus.com · Feb 11
Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
prnewswire.com · Feb 6
Tharimmune Elects Jill Sommers and William Wiley to Board of Directors
prnewswire.com · Feb 2
Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost
defenseworld.net · Jan 31
Tharimmune Announces Expanded Role as Super Validator on Canton Network
prnewswire.com · Jan 26
Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization
seekingalpha.com · Jan 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.